The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naïve chronic lymphocytic leukemia patients.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2024-03-08 DOI:10.1159/000538055

Shirley Shapira, Naama Hirschberger, Yishai Ofran, Barak Mizrahi, Esti Mandel, Ohad Benjamini, Noa Rabinowicz, Adi Zoref-Lorenz

{"title":"The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naïve chronic lymphocytic leukemia patients.","authors":"Shirley Shapira, Naama Hirschberger, Yishai Ofran, Barak Mizrahi, Esti Mandel, Ohad Benjamini, Noa Rabinowicz, Adi Zoref-Lorenz","doi":"10.1159/000538055","DOIUrl":null,"url":null,"abstract":"Introduction: Mind-Body Intervention (MBI) serves as supportive aid in oncology. We hypothesized that MBI could impact the progression of Chronic Lymphocytic Leukemia (CLL) in the 'watch and wait' (w&w) phase.Methods: MBI was utilized in a non-randomized prospective controlled study between 02/2020-02/2022 in 76 treatment-naïve CLL patients in the w&w phase (37 intervention and 39 control patients). The primary and secondary endpoints were prolongation of Lymphocyte Doubling Time (LDT) and treatment-free survival (TFS). The prolongation of LDT was compared at 0, 180, 360, and 540 days using paired t-tests. TFS was compared between intervention and control groups using the log-rank test. Cox proportional hazards models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for TFS in the intervention group compared to the control, stratified by the study covariates.Results: MBI prolonged LDT at all time points, including at day 360 (Median of 2.47 years; CI 1.05-3.9; p= 0.001). TFS at 18 months was longer in the intervention group compared to the control group (HR 0.23; CI 0.06-0.79, p=0.01).Conclusions: MBI was associated with prolonged LDT and TFS in patients with CLL in the w&w phase. These results provide a basis for a larger randomized-control trial.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Mind-Body Intervention (MBI) serves as supportive aid in oncology. We hypothesized that MBI could impact the progression of Chronic Lymphocytic Leukemia (CLL) in the 'watch and wait' (w&w) phase.

Methods: MBI was utilized in a non-randomized prospective controlled study between 02/2020-02/2022 in 76 treatment-naïve CLL patients in the w&w phase (37 intervention and 39 control patients). The primary and secondary endpoints were prolongation of Lymphocyte Doubling Time (LDT) and treatment-free survival (TFS). The prolongation of LDT was compared at 0, 180, 360, and 540 days using paired t-tests. TFS was compared between intervention and control groups using the log-rank test. Cox proportional hazards models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for TFS in the intervention group compared to the control, stratified by the study covariates.

Results: MBI prolonged LDT at all time points, including at day 360 (Median of 2.47 years; CI 1.05-3.9; p= 0.001). TFS at 18 months was longer in the intervention group compared to the control group (HR 0.23; CI 0.06-0.79, p=0.01).

Conclusions: MBI was associated with prolonged LDT and TFS in patients with CLL in the w&w phase. These results provide a basis for a larger randomized-control trial.

查看原文本刊更多论文

身心干预对未经治疗的慢性淋巴细胞白血病患者淋巴细胞倍增时间和无治疗生存期的影响。

简介身心干预（MBI）是肿瘤学的辅助疗法。我们假设，在 "观察和等待"（w&w）阶段，MBI 可以影响慢性淋巴细胞白血病（CLL）的进展：在 2020 年 2 月至 2022 年 2 月期间进行的一项非随机前瞻性对照研究中，对 76 名处于观察和等待阶段的治疗无效的 CLL 患者（37 名干预患者和 39 名对照患者）使用了 MBI。主要和次要终点是淋巴细胞倍增时间（LDT）和无治疗生存期（TFS）的延长。淋巴细胞倍增时间的延长采用配对 t 检验法在 0、180、360 和 540 天进行比较。采用对数秩检验比较干预组和对照组的无治疗生存期。使用 Cox 比例危险模型计算干预组与对照组相比的 TFS 危险比（HR）和 95% 置信区间（CI），并根据研究协变量进行分层：MBI延长了所有时间点的LDT，包括第360天（中位数为2.47年；CI为1.05-3.9；P= 0.001）。与对照组相比，干预组在18个月时的TFS更长（HR 0.23; CI 0.06-0.79, p=0.01）：结论：MBI与CLL患者W&W阶段的LDT和TFS延长有关。这些结果为开展更大规模的随机对照试验提供了依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.